AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.
William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other
William Blair initiated coverage on Eyenovia Inc (NASDAQ: EYEN), a biopharma company focused on developing therapies based on its Optejet device, which leverages a microdose array print (MAP) technology that allows consistent, reproducible dosing of ophthalmic drugs.
William Blair initiated coverage on Eyenovia Inc EYEN, a biopharma company focused on developing therapies based on its Optejet device, which leverages a…